BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 17504989)

  • 1. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
    McConville P; Hambardzumyan D; Moody JB; Leopold WR; Kreger AR; Woolliscroft MJ; Rehemtulla A; Ross BD; Holland EC
    Clin Cancer Res; 2007 May; 13(10):2897-904. PubMed ID: 17504989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADC texture--an imaging biomarker for high-grade glioma?
    Brynolfsson P; Nilsson D; Henriksson R; Hauksson J; Karlsson M; Garpebring A; Birgander R; Trygg J; Nyholm T; Asklund T
    Med Phys; 2014 Oct; 41(10):101903. PubMed ID: 25281955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
    Sijens PE; Heesters MA; Enting RH; van der Graaf WT; Potze JH; Irwan R; Meiners LC; Oudkerk M
    Cancer Invest; 2007 Dec; 25(8):706-10. PubMed ID: 18058466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic history of low-grade gliomas before and after temozolomide treatment.
    Ricard D; Kaloshi G; Amiel-Benouaich A; Lejeune J; Marie Y; Mandonnet E; Kujas M; Mokhtari K; Taillibert S; Laigle-Donadey F; Carpentier AF; Omuro A; Capelle L; Duffau H; Cornu P; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Ann Neurol; 2007 May; 61(5):484-90. PubMed ID: 17469128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
    Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
    Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
    Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
    Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
    Bower M; Newlands ES; Bleehen NM; Brada M; Begent RJ; Calvert H; Colquhoun I; Lewis P; Brampton MH
    Cancer Chemother Pharmacol; 1997; 40(6):484-8. PubMed ID: 9332462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
    Ouyang M; White EE; Ren H; Guo Q; Zhang I; Gao H; Yanyan S; Chen X; Weng Y; Da Fonseca A; Shah S; Manuel ER; Zhang L; Vonderfecht SL; Alizadeh D; Berlin JM; Badie B
    PLoS One; 2016; 11(2):e0148139. PubMed ID: 26829221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
    Momota H; Nerio E; Holland EC
    Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
    Lin L; Wang G; Ming J; Meng X; Han B; Sun B; Cai J; Jiang C
    Tumour Biol; 2016 Nov; 37(11):15333-15339. PubMed ID: 27704357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas.
    Carceller F; Jerome NP; Fowkes LA; Khabra K; Mackinnon A; Bautista F; Marshall LV; Vaidya S; Mandeville H; Morgan V; Leach MO; Koh DM
    Pediatr Hematol Oncol; 2019 Mar; 36(2):103-112. PubMed ID: 30978130
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
    Kocher M; Kunze S; Eich HT; Semrau R; Müller RP
    Strahlenther Onkol; 2005 Mar; 181(3):157-63. PubMed ID: 15756519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
    Friedman HS
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):35-40. PubMed ID: 10866348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer.
    Connolly NP; Stokum JA; Schneider CS; Ozawa T; Xu S; Galisteo R; Castellani RJ; Kim AJ; Simard JM; Winkles JA; Holland EC; Woodworth GF
    PLoS One; 2017; 12(3):e0174557. PubMed ID: 28358926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis.
    Ferletta M; Uhrbom L; Olofsson T; Pontén F; Westermark B
    Mol Cancer Res; 2007 Sep; 5(9):891-7. PubMed ID: 17855658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
    Galbán S; Lemasson B; Williams TM; Li F; Heist KA; Johnson TD; Leopold JS; Chenevert TL; Lawrence TS; Rehemtulla A; Mikkelsen T; Holland EC; Galbán CJ; Ross BD
    PLoS One; 2012; 7(4):e35857. PubMed ID: 22536446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.